Yale SPORE in Lung Cancer News

On February 6, 2026, YCC CRTEC welcomed students from Hill Regional Career High School to our Cancer Research Discovery Program (CRDP), a day designed to introduce them to careers in cancer research and medicine.

While the study is a signal that time of day for immunotherapy infusion is worth investigating further, Roy Herbst, the deputy director of the Yale Cancer Center, said he’s not going to change practice based on the trial. “It’s intriguing. This is maybe a wake-up call to look at it more," Herbst said.

A dozen awards honored 15 people at January's Yale Cancer Center Annual Awards for work in 2025.

Medical oncologist Dr. Roy S. Herbst explains the importance of cancer screenings

Researchers uncovered potential treatment strategies for stromal sarcoma of the uterus by establishing a more detailed understanding of the aggressive tumors at the molecular level.

Nytimes article about antibodies that can defeat cancer -- could they become a treatment?

Combination chemotherapy has long been a mainstay of cancer treatment, although early mechanism-based therapies showed little promise. More than 50 years later, this foundational principle — in which biologic rationale is used to guide the choice of treatment combinations — is being applied to the leading cause of cancer-related deaths: lung cancer. Today, genomic profiling, targeted agents, and strategies informed by resistance mechanisms are reshaping care for epithelial growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC).

Veronica Chiang, MD, professor of neurosurgery, is currently leading several clinical trials seeking to improve treatments for brain metastases, or cancers that has spread to the brain). She recently sat down for an interview about this important work.

Legendary singer songwriter Barry Manilow reveals that he's been diagnosed with lung cancer. We'll ask a lung cancer specialist what sort of treatment may lie ahead.